Clinical Trial Update: Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AI model-guided neoadjuvant anti-HER2 targeted therapy for breast cancer; the study status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AI-guided anti-HER2 targeted therapy

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING